JPRN-jRCT1080221863未知3 期
A Phase 3 Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Male or female patients aged 18 years or older (For Japan only- male or female patients aged 20 years or older)
- •- Cytological or histological confirmation of NSCLC other than predominantly squamous cell histology with an activating EGFR TK mutation as determined locally
- •- Patients suitable to start chemotherapy.
排除标准
- •- Prior chemotherapy or other systemic anti-cancer treatment (excluding gefitinib).
- •- Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety Study of Romiplostim in Paediatrics with Immune ThrombocytopeniaEUCTR2010-018426-39-Outside-EU/EEAAmgen Inc.60
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1EUCTR2020-003136-25-FRCyclo Therapeutics, Inc.105
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1iemann Pick Disease Type C1MedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003136-25-ESCyclo Therapeutics, Inc.105
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1iemann Pick Disease Type C1MedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003136-25-DECyclo Therapeutics, Inc.105
招募中
3 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C12024-518266-27-00Cyclo Therapeutics Inc.36